-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

Benzinga·07/08/2026 17:23:27
Listen to the news
B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.